Alaunos Therapeutics Says $350 Million Financing Restores Nasdaq Equity Compliance

What happened

Alaunos Therapeutics, Inc. (Nasdaq: TCRT), a pharmaceutical company, disclosed in a Form 8-K filed October 21, 2026, that it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain at least $2,500,000 in stockholders' equity for continued listing.

The company had been under pressure since April 9, 2026, when Nasdaq's Listing Qualifications staff sent a deficiency letter. According to the filing, Alaunos reported stockholders' equity of $2,153,000 in its annual report for the fiscal year ended December 31, 2025, below the $2.5 million minimum. The letter also stated the company did not meet either alternative standard: $35 million in market value of listed securities or $500,000 in net income from continuing operations in the most recent fiscal year or two of the last three.

On October 5, 2026, Nasdaq notified Alaunos that its securities were subject to delisting unless the company requested a hearing before the Nasdaq Hearings Panel. Alaunos did so, which stayed any suspension or delisting action. The hearing is scheduled for November 10, 2026.

The filing attributes the regained compliance to two transactions completed in mid-October: the company's acquisition of Velaris Therapeutics, Inc. and a private placement of common and preferred stock that raised approximately $350.0 million in gross proceeds before fees and expenses.

Alaunos said it expects the hearing before the Panel to be cancelled once Nasdaq staff confirms compliance, but cautioned that there is no assurance Nasdaq will concur with its determination or as to the timing of any confirmation.

The financing and the waiver

The private placement, completed October 14, 2026, involved 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C Non-Voting Convertible Preferred Stock at $1,435.70 per share.

The Series C preferred stock carries a cash settlement right: if stockholders have not approved conversion of the preferred stock and a related increase in authorized common shares, then beginning six months after issuance a holder can require the company to settle a conversion in cash equal to the fair value of the common shares that would otherwise be issued.

Fairmount Healthcare Fund II, L.P., which led the financing, delivered a waiver covering 6,268 shares of Series C preferred stock, valued at approximately $9.0 million. Under the waiver, the company's obligation on conversion of those shares is to deliver common stock rather than cash. The waiver terminates automatically once stockholders approve the conversion and the authorized-share increase takes effect.

Pending those stockholder approvals, Alaunos said it expects to classify most of the preferred shares issued in the merger and financing outside of permanent stockholders' equity, while classifying the waived shares and the common stock issued in the financing within permanent stockholders' equity. That classification is what underpins the company's compliance conclusion.

What this means

A Form 8-K is the current report public companies file with the SEC to announce material events between quarterly and annual reports. Item 3.01, cited here, specifically covers notice of delisting or failure to meet a continued listing rule. So this filing is the company's formal disclosure that it spent most of 2026 below Nasdaq's equity floor and is now telling the market it has fixed the problem.

The Nasdaq Capital Market's $2.5 million stockholders' equity rule is a balance-sheet test: it compares what a company owns to what it owes. Small, loss-making drug developers often fall below it because years of research spending erode equity. Nasdaq allows a company to submit a plan to regain compliance, and if that fails, a hearing before the Panel, which pauses delisting while the case is pending.

The mechanics of the fix matter here. Alaunos did not become profitable; it raised money. A $350 million private placement adds cash and, depending on accounting, equity. Preferred stock is a class of shares that typically has rights senior to common stock; a convertible preferred can be exchanged for common shares. The cash settlement right was a risk: if stockholders did not approve conversion, holders could demand cash instead of stock, which would drain the very equity the company needs to stay listed. Fairmount's waiver removes that cash obligation for about $9 million of the preferred, allowing those shares to count toward equity.

The next scheduled event is the November 10 hearing. If Nasdaq staff confirms compliance first, the filing says the hearing will be cancelled and the matter closed. The company also noted that its third-quarter 10-Q, covering the period ended September 30, 2026, will not reflect the merger or financing because both closed in October, and that Nasdaq will keep monitoring compliance and could revisit delisting if the 2026 annual report does not show compliance.